1810022C23Rik Activators
1810022C23Rik Activators are a diverse array of chemical compounds that indirectly promote the functional activity of 1810022C23Rik through specific intracellular signaling mechanisms. Forskolin, by increasing cAMP levels, activates PKA, which could enhance 1810022C23Rik activity through phosphorylation of associated substrates. Epigallocatechin gallate, as a tyrosine kinase inhibitor, minimizes competitive signaling interference, potentially augmenting 1810022C23Rik's role in its respective signaling pathways. Sphingosine-1-phosphate, through its receptor-mediated signaling, modifies lipid pathways, which can lead to the activation of 1810022C23Rik, while A23187 increases intracellular calcium, enhancing the protein's activity through calcium-dependent signaling mechanisms. LY294002 and Wortmannin, both PI3K inhibitors, may disrupt AKT signaling, indirectly promoting 1810022C23Rik activity through altered PI3K/AKT pathway dynamics. 1810022C23Rik Activators is a designation for a class of chemical compounds that actively promote the expression of the 1810022C23Rik gene.
This gene is implicated in a variety of cellular processes and the modulation of its activity is of significant interest in the field of molecular biology. The search for these activators typically commences with a thorough high-throughput screening (HTS) process. In this screening, libraries comprising thousands of small molecules are assayed for their capacity to enhance the gene's activity. To facilitate the detection of gene activation, a reporter assay system is employed, wherein the promoter of the 1810022C23Rik gene is fused to a reporter gene such as luciferase, which emits light upon activation. When a compound successfully activates the promoter, the reporter gene's expression results in luminescence, the intensity of which serves as an indicator of promoter activity. Compounds that yield a pronounced increase in luminescent output are flagged for further evaluation, as this suggests a specific activating effect on the 1810022C23Rik gene.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate inhibits multiple tyrosine kinases, resulting in the upregulation of pathways where 1810022C23Rik functions as a key modulator, thus indirectly enhancing 1810022C23Rik activity by reducing competitive signaling interference. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate binds to its receptors, leading to downstream signaling cascades that can activate 1810022C23Rik by altering lipid signaling pathways that the 1810022C23Rik protein participates in. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 acts as an ionophore that increases intracellular calcium levels, which may enhance 1810022C23Rik activity through calcium-dependent signaling pathways that implicate 1810022C23Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor that alters AKT signaling; by modulating this pathway, it indirectly promotes the activity of 1810022C23Rik if 1810022C23Rik is involved in the PI3K/AKT pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 is a selective MEK inhibitor that affects the MAPK/ERK pathway, which may lead to the enhancement of 1810022C23Rik activity by altering the signaling pathways that 1810022C23Rik is involved in. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, by inhibiting this pathway, it could shift cellular signaling to support processes where 1810022C23Rik is functionally important, thereby enhancing the activity of 1810022C23Rik. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels, which potentially enhances 1810022C23Rik by activating calcium-dependent signaling systems that involve 1810022C23Rik. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a PKC activator that modulates protein kinase C signaling, which can enhance the activity of 1810022C23Rik through PKC-dependent signaling events that 1810022C23Rik is part of. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor that may selectively activate 1810022C23Rik-related pathways by alleviating specific kinase-mediated repression of signaling processes that involve 1810022C23Rik. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that can modulate downstream signaling, potentially enhancing the activity of 1810022C23Rik if the 1810022C23Rik protein is involved in the PI3K/Akt pathway. | ||||||